Seed-competent high-molecular-weight tau species accumulates in the cerebrospinal fluid of Alzheimer's disease mouse model and human patients

Annals of Neurology

Volumn 80, Issue 3, 2016, Pages 355-367

  Takeda, Shuko ^a,f   Commins, Caitlin ^a   DeVos, Sarah L ^a   Nobuhara, Chloe K ^a   Wegmann, Susanne ^a   Roe, Allyson D ^a   Costantino, Isabel ^a   Fan, Zhanyun ^a   Nicholls, Samantha B ^a   Sherman, Alexis E ^a   Trisini Lipsanopoulos, Ana T ^b   Scherzer, Clemens R ^b   Carlson, George A ^c   Pitstick, Rose ^c   Peskind, Elaine R ^d,e   Raskind, Murray A ^d,e   Li, Ge ^d,e   Montine, Thomas J ^d   Frosch, Matthew P ^a   Hyman, Bradley T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MCLAUGHLIN RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^f OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPSY; BIOACCUMULATION; BRAIN INTERSTITIAL FLUID; CONTROLLED STUDY; DISEASE COURSE; EXTRACELLULAR SPACE; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEK293 CELL LINE; HIGH MOLECULAR WEIGHT TAU SPECIES; HUMAN; HUMAN CELL; IN VITRO STUDY; LUMBAR PUNCTURE; MALE; MIDDLE AGED; MOLECULE; MOUSE; MOUSE MODEL; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; VERY ELDERLY;

EID: 84985947118     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24716     Document Type: Article

References (28)

1. Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 1984;225:1168–1170.
2. Serrano-Pozo A, et al. Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. J Neuropathol Exp Neurol 2013;72:1182–1192.
3. Polydoro M, et al. Reversal of neurofibrillary tangles and tau-associated phenotype in the rTgTauEC model of early Alzheimer's disease. J Neurosci 2013;33:13300–13311.
4. de Calignon A, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 2012;73:685–697.
5. Liu L, et al. Trans-synaptic spread of tau pathology in vivo. PLoS One 2012;7:e31302.
6. Harris JA, et al. Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits. PLoS One 2012;7:e45881.
7. Takeda S, et al. Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer's disease brain. Nat Commun 2015;6:8490.
8. Barten DM, et al. Tau transgenic mice as models for cerebrospinal fluid tau biomarkers. J Alzheimers Dis 2011;24(suppl 2):127–141.
9. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131–144.
10. Hampel H, et al. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol 2010;45:30–40.
11. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet. Neurol 2003;2:605–613.
12. Jack CR, Jr., et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119–128.
13. Mattsson N, et al. Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology 2012;78:468–476.
14. Hall GF, Saman S. Death or secretion?. The demise of a plausible assumption about CSF-tau in Alzheimer disease? Commun Integr Biol 2012;5:623–626.
15. Bian H, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 2008;70:1827–1835.
16. Santacruz K, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005;309:476–481.
17. Herskovits AZ, Locascio JJ, Peskind ER, Li G, Hyman BT. A Luminex assay detects amyloid beta oligomers in Alzheimer's disease cerebrospinal fluid. PLoS One 2013;8:e67898.
18. McKhann G, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939–944.
19. Holmes BB, et al. Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci U S A 2014;111:E4376–E4385.
20. Sanders DW, et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 2014;82:1271–1288.
21. Takeda, S, et al. Novel microdialysis method to assess neuropeptides and large molecules in free-moving mouse. Neuroscience 2011;186:110–119.
22. Takeda S, et al. Brain interstitial oligomeric amyloid beta increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease. FASEB J 2013;27:3239–3248.
23. Larner AJ. The cerebellum in Alzheimer's disease. Dement Geriatr Cogn Disord 1997;8:203–209.
24. Clavaguera F, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 2009;11:909–913.
25. Ahmed Z, et al. A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol 2014;127:667–683.
26. Mirbaha H, Holmes BB, Sanders DW, Bieschke J, Diamond MI. Tau trimers are the minimal propagation unit spontaneously internalized to seed intracellular aggregation. J Biol Chem 2015;290:14893–14903.
27. Hampel H, Blennow K. CSF tau and beta-amyloid as biomarkers for mild cognitive impairment. Dialogues Clin Neurosci 2004;6:379–390.
28. Galasko D, et al. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology 1997;48:632–635.